Loading...
Although we have effective treatment to suppress hepatitis B virus (HBV) infection, clearance of infection is rare. Nucleic acid polymers (NAPs), such as REP 2139 and REP 2165, inhibit assembly and secretion of HBV subviral particles. To evaluate the use of NAP-based treatment for HBV infection, international investigators conducted an industry-supported, open-label, randomized, controlled, phase II study of 40 treatment-naive patients with HBeAg-negative chronic HBV infection.
Patients initially received 24 weeks of tenofovir disoproxil (TDF) and were then randomized to receive either 48 weeks of NAP-based treatment (TDF) plus peginterferon plus REP 2139 or REP 2165 or 24 weeks of control treatment (TDF plus peginterferon) followed by 48 we…